Risk of Hepatocellular Carcinoma Decreases After Antiviral Therapy–Induced HBsAg Seroclearance
Journal of Gastroenterology and Hepatology · 2025
DOI: 10.1111/jgh.16973 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2025. Verfasst von Han Ah Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Antiviral Agents, Hepatitis B Surface Antigens. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Ministry of Science and ICT, South Korea.
Abstract (Originalsprache)
Background
Antiviral therapy (AVT) reduces the risk of hepatitis B virus–related hepatocellular carcinoma (HCC).
Aims
The difference in risk of HCC after hepatitis B surface antigen (HBsAg) seroclearance to the AVT status was explored.
Methods
Patients with chronic hepatitis B who achieved HBsAg seroclearance were retrospectively evaluated. The primary outcome was the development of HCC after HBsAg seroclearance.
Results
Of the study population, 1280 (84.2%) and 241 (15.8%) patients achieved HBsAg seroclearance without (spontaneous clearance group) and with AVT (AVT‐induced clearance group), respectively. HCC cumulative incidence was comparable between the two groups (hazard ratio [HR] = 0.461; log‐rank test, p = 0.197), whereas it was significantly lower in the AVT‐induced HBsAg clearance group than in the spontaneous HBsAg clearance group in inverse probability of treatment weighting analysis (HR = 0.442; log‐rank test, p = 0.004). In multivariate analysis, spontaneous HBsAg clearance, albumin–bilirubin (ALBI) grade ≥ 2, cirrhosis, and platelet count < 50 × 10 9 /L were independently associated with the increased risk of HCC. The newly established antiviral therapy, cirrhosis, ALBI, and platelet count (ACAP) scores had a C‐index of 0.765, and the time‐dependent areas under the curve of HCC prediction at 5 and 8 years were 0774 and 0.823, respectively.
Conclusion
The risk of HCC differed according to the AVT status after HBsAg seroclearance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
- Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
- Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
- Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
- Yonsei Liver Center, Severance Hospital, Seoul, South Korea.
ORCID-Profile: Han Ah Lee, Yeon Seok Seo, Dong Hyun Sinn, Sang Hoon Ahn, Beom Kyung Kim, Seung Up Kim
Förderung
- Ministry of Science and ICT, South Korea
Zitieren
APA
Lee, H. A., Lee, H. W., Seo, Y. S., Sinn, D. H., Ahn, S. H., Kim, B. K., & Kim, S. U. (2025). Risk of Hepatocellular Carcinoma Decreases After Antiviral Therapy–Induced HBsAg Seroclearance. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16973
Vancouver
Lee HA, Lee HW, Seo YS, Sinn DH, Ahn SH, Kim BK, et al. Risk of Hepatocellular Carcinoma Decreases After Antiviral Therapy–Induced HBsAg Seroclearance. Journal of Gastroenterology and Hepatology. 2025. doi:10.1111/jgh.16973
BibTeX
@article{Lee2025,
author = {Lee, Han Ah and Lee, Hyun Woong and Seo, Yeon Seok and Sinn, Dong Hyun and Ahn, Sang Hoon and Kim, Beom Kyung and Kim, Seung Up},
title = {Risk of Hepatocellular Carcinoma Decreases After Antiviral Therapy–Induced HBsAg Seroclearance},
journal = {Journal of Gastroenterology and Hepatology},
year = {2025},
doi = {10.1111/jgh.16973}
}
EUVIMED